Skip to Main Content

UBIO  ProShares UltraPro Nasdaq Biotechn…
Exchange-Traded Fund
NASDAQ

Morningstar Summary

Ratings & Reports

  • Overall
    as of --
    Star Rating: 0Not Rated
    Out of -- funds
  • 3 Year
    Star Rating: 0Not Rated
    Out of -- funds
  • 5 Year
    Star Rating: 0Not Rated
    Out of -- funds
  • 10 Year
    Star Rating: 0Not Rated
    Out of -- funds

Historical Risk

  • Low
  • Below Average
  • Avg
  • Above Average
  • High

Historical Return

  • Low
  • Below Average
  • Avg
  • Above Average
  • High

Morningstar Style Box

Market Cap vs. Investment Style
Selected Values: Investment Style: Mid, Market Cap: Growth
Value
Blend
Growth
Large
Mid
Small

Price Movement of UBIO

Chart for Price Movement
UBIO is down -8.50% over the last 3 days.
Bid/Ask1$27.50 / --
Open$35.10
Previous Close$35.00
Day Low/High
Last Price
$32.08  0% or $0.01 from its Day low
$32.07
$35.10
52 Week Range
Last Price
$32.08  22% or $4.10 from its 52 Week high
$17.37
6/27/2016
$36.18
6/22/2017
Price/Earnings20.86x
Price/Cash Flow14.65x
Price/Revenue5.72x

Fund Detail

as of 5/31/2017

Profile

Profile
Total Net Assets$34.2 M
Premium/Discount0.14%
Portfolio Turnover--
Total Holdings173
Fund TypeETF
Transaction FeeYes

Distributions and Yield

Distributions and Yield
Distribution Yield0.00%
Most Recent Dividend--
Previous Pay Date--
Ex-Date--
Distribution FrequencyQuarterly
SEC Yield--

Total Returns

as of 5/31/2017

Standardized Returns

Standardized Returns: Monthly
Description3 Month1 Year3 Year5 Year10 YearInception3 Month1 Year3 Year5 Year10 YearInception3 Month1 Year3 Year5 Year10 YearInception
UBIO Market Price
33.95%55.45%-------40.67%-12.54%-9.86%-------49.60%31.08%16.85%-------50.33%
UBIO NAV
30.38%80.50%-------40.67%-12.70%-9.48%-------50.74%31.73%16.79%-------51.51%
Trading--Leveraged Equity
Morningstar Category
------------3.07%15.53%20.57%18.63%6.36%--3.19%9.51%24.83%16.48%5.43%--
S&P 500
Index
4.46%17.81%9.80%15.24%7.25%10.62%2.57%17.47%10.14%15.42%6.94%10.60%6.07%17.17%10.37%13.30%7.51%10.59%
View Performance >

Top 5 Holdings

as of 5/31/2017
Top 5 Holdings
--Nasdaq Biotechnology Index Swap Societe Generale139.55%
--Nasdaq Biotechnology Index Swap Bank Of America Na45.02%
--Nasdaq Biotechnology Index Swap Ubs Ag24.48%
REGNOpens Flyout Module that includes Quote information for linked symbolRegeneron Pharmaceuticals Inc7.23%
CELGOpens Flyout Module that includes Quote information for linked symbolCelgene Corp6.95%
Total
223.24%
More Holdings >

Top Sectors

as of 5/31/2017
Top SectorsTop Sectors
Sector% of Holdings
Healthcare99.94%
Technology0.06%
Utilities0.00%
Industrials0.00%
Total100.00%
Sign in to see if you own shares.
Additional Trading Options
Fund Highlights
Fund Strategy
The investment seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the NASDAQ Biotechnology Index® (the "index"). The fund invests in securities and derivatives that the advisor believes, should have similar daily return characteristics as three times the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.
Morningstar Category
These funds seek to generate returns equal to a fixed multiple of the short-term returns of an equity index. The compounding of short-term returns results in performance that does not correspond to those of investing in the index with external leverage. For example, a fund attempting to achieve 2 times the returns of a given index on a daily basis is unlikely to deliver anything like 2 times the index's returns over periods longer than one day. Many of these funds seek to generate a multiple of the daily or weekly return of the reference index. Trading funds are not considered suitable for a long-term investor and are designed to be used by active traders.
  • Inception Date
    06/22/2015
  • 0.95%
    Net Expense may include reimbursements or fee waivers, which may be voluntary or contractual and may expire. See prospectus for more details.
  • Gross Expense Ratio
    1.28%
  • Index Fund
    Yes
  • Leveraged Fund
    Yes
  • Socially Conscious
    No
  • Actively Managed
    No
  • Fund Family
Opens a modal dialogOpens a modal dialogOpen flyout contentOpens a new window